CFT8919 Pre-Clinical Data Investor Call
June 7, 2021
Forward-looking Statements and Intellectual Property
Forward-looking Statements
The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.
Intellectual Property
C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
© 2021 C4 Therapeutics, Inc. | 2 |
Today's Agenda
Topic | Participants |
Introductions | Kendra Adams, SVP Communications & |
Investor Relations | |
Opening Remarks | Andrew Hirsch, President and CEO |
CFT8919 Pre-clinical Data Overview | Adam Crystal, M.D., Ph.D., CMO |
Q&A Session | Andrew Hirsch, Adam Crystal and Stew |
Fisher, CSO |
© 2021 C4 Therapeutics, Inc. | 3 |
What You Will Hear Today
- CFT8919 is an orally bioavailable, selective, allosteric degrader of EGFR L858R
- Active in vitro and in vivo in models with secondary EGFR mutations
- Demonstrates intracranial activity indicating potential to prevent or treat brain metastases in patients with EGFR L858R-driven tumors
- 25-45%of mutant EGFR NSCLC is driven by L858R activating mutation; these patients are not adequately addressed with current EGFR therapies
- Pre-clinicaldata suggests CFT8919 has path to registration in EGFR patients who develop resistance to osimertinib
Sources: Li, K et al. Oncol Rep 37, 1347-1358 (2017);Jin Y. et al. Scientific Reports 6:31636 (2016); Soria, J.-C. et al. NEJM 378, 113-125 (2018)
© 2021 C4 Therapeutics, Inc. | 4 |
TORPEDO Platform Has Delivered a Robust Degrader Pipeline; Four Clinical Programs Expected by End of 2022
Target | Indication(s) | Discovery | Preclinical | Clinical | Ownership |
IKZF1/3 (CFT7455) | Multiple Myeloma & Lymphoma | ||||
BRD9 (CFT8634) | Synovial Sarcoma & SMARCB1 Deleted | ||||
Tumors | |||||
EGFR (CFT8919) | Drug-Resistant EGFR+ NSCLC | ||||
BRAF V600E | Drug-Resistant BRAF mutant | ||||
Tumors | |||||
RET | Drug-ResistantRET-Altered Tumors | ||||
Transcriptional Control | Undisclosed Solid Tumors | ||||
Cancer Signaling | Undisclosed Cancers | ||||
Transcriptional Control | Undisclosed Liquid Tumors | ||||
Cancer Signaling | Undisclosed Solid Tumors | ||||
Nine Additional Undisclosed Collaborator Programs in Discovery
© 2021 C4 Therapeutics, Inc. | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
C4 Therapeutics Inc. published this content on 07 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 18:17:01 UTC.